Aims: Safety evaluations of tranexamic acid (TXA) remain sparse, especially with respect to its impact on long-term outcomes in patients undergoing on-pump coronary artery bypass grafting (CABG). We hypothesized that the effects of TXA on perioperative bleeding and allogeneic transfusion and its impact on long-term clinical outcomes of patients receiving on-pump CABG are superior to those in the control group.
| INTRODUC TI ON
Excessive bleeding and blood transfusion are associated with increased postoperative morbidity and mortality in patients undergoing on-pump coronary artery bypass grafting (CABG). 1 Since the suspension of aprotinin in 2008, administration of tranexamic acid (TXA) has become the main method to prevent major blood loss in cardiac surgery. 2 As an antifibrinolytic agent, TXA acts by forming a reversible complex with plasminogen and plasmin through lysinebinding sites, blocking interaction with the specific lysine residues of fibrin. TXA also preserves platelet function by reducing the effect of plasmin on platelet glycoprotein 1b receptors. 3 Some meta-analyses have shown that TXA reduces the risk of blood loss and transfusion among patients undergoing cardiac surgery. 4, 5 However, the optimal dosing regimen remains unclear.
One meta-analysis showed a dose-dependent association between TXA and a risk of seizures. 6 Other studies recently showed that moderate to high doses of TXA in cardiac surgery are associated with an increased risk of seizures. 7, 8 Therefore, careful use of TXA at a low dose is suggested. Moreover, TXA has been shown to increase thrombus formation in a dose-dependent manner in animal models. 9 However, the effect of TXA on thromboembolic events in clinical practice remains controversial. The discontinuation of aprotinin has made the safety evaluation of clinical interventions more important but also more difficult. To date, safety evaluations of TXA remain sparse, especially with respect to its impact on long-term outcomes.
The aim of the current study was to evaluate the effects of TXA on perioperative bleeding and allogeneic transfusion in addition to its impact on long-term clinical outcomes in on-pump CABG surgery.
| MATERIAL S AND ME THODS

| Study design
This study was a prospective, randomized, placebo-controlled trial with a superiority design. The working hypothesis was that TXA Eligible patients were randomly assigned to the TXA group or placebo group. The randomization sequence was generated by computer in permuted blocks using a 1:1 ratio and was masked in sealed, sequentially numbered opaque envelopes. Patient recruitment, randomization, and blinding were conducted and supervised by an independent committee. The participants, medical staff, and investigators were unaware of the treatment allocation until discharge of the last patient. The hospital pharmacy prepared the study medication. Identical syringes labeled with the randomization number contained transparent solution, which was either TXA (50 mg/mL) or saline solution. After induction, the medication was intravenously administered with a pump in a 0.2-mL/kg bolus over a 10-minute period followed by maintenance at 0.2 mL/kg/h throughout the surgery, fulfilling the dosage regimen of TXA as a 10-mg/kg bolus with maintenance at 10 mg/kg/h. Randomly assigned patients were followed up by means of questionnaire or telephone at 1, 3, 5, and 7 years after hospital discharge, with all data fields centrally adjudicated by blinded investigators.
| Measurements
The primary study end point was the intraoperative and postoperative allogeneic red blood cell (RBC) transfusion volume and exposure. 
| Statistical analyses
The sample size was calculated based on the volume and exposure of allogeneic RBC transfusion using two-tailed tests at an alpha level of CIs. The Mantel-Haenszel method was applied to calculate the RR The incidence of follow-up morbidity and mortality was calculated with the Kaplan-Meier method and compared using the log-rank test.
All tests were two-sided, and a probability value of <0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC). The authors had full access to the data and take responsibility for its integrity.
| RE SULTS
Patient screening, enrollment, and follow-up data are presented in Figure 1 . During the study period, 7860 patients underwent cardiac surgery in the hospital; of these, 767 underwent primary, isolated, selective on-pump CABG. In total, 210 patients were randomly assigned to one of the two treatment groups, and 202 patients were included in the per-protocol analysis. The reason for dropout was the withholding of consent (five patients in the TXA group and three in the placebo group). Therefore, 100 patients in the TXA group and 102 patients in the placebo group were assessed. During the 7-year study period, 39 patients were lost to follow-up (26 in the TXA group and 13 in the placebo group). Finally, 74 patients in the TXA group and 89 patients in the placebo group fulfilled the 7-year follow-up.
| Baseline characteristics and perioperative data
The baseline characteristics, including demographics, clinical history, risk factors, and preoperative medications, were balanced between the two groups (Table 1) .
Perioperative outcomes, including the intraoperative data and postoperative time course, were comparable between the two groups except for the postoperative hospital length of stay, which was longer in the placebo group (8.4 ± 2.0 days) than in the TXA group (7.8 ± 1.6 days, P = 0.03) ( Table 2 ).
| Bleeding and transfusion outcomes
The postoperative bleeding and allogeneic transfusion volumes were significantly different between the two groups (Table 3) 
| Postoperative mortality, morbidity, and adverse outcomes
There was no in-hospital mortality in the TXA group. One (1.0%) patient in the placebo group died of postoperative renal failure (P = 0.32).
F I G U R E 1 CONSORT flow chart
There were no significant differences in in-hospital morbidity or adverse outcomes between the two groups. Specifically, two (2.00%) patients in the TXA group and none in the placebo group developed seizures (P = 0.15) ( Table 4) .
| Seven-year follow-up morbidity and mortality
The duration of follow-up was 84 months, and 163 (80.7%) patients completed the 7-year follow-up. Overall, four deaths 
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occurred among the 100 patients in the TXA group and six deaths occurred among the 102 patients in the placebo group during the 7-year follow-up period. There was no difference in mortality between the TXA and placebo groups (4.0% vs 5.9% at 84 months; P = 0.60). No seizures occurred in either group during the 7 years of follow-up after discharge. Except for myocardial infarction, the occurrence of thrombotic events showed no significant differences between the two groups during the follow-up. The prevalence of myocardial infarction in the placebo group at 5, 6, and 7 years was 2.0%, 3.9%, and 4.9%, respectively. However, no myocardial infarction occurred in the TXA group during the 7-year follow-up. The TXA group had a lower rate of myocardial infarction than did the placebo group (0.0% vs 4.9% at 84 months; P = 0.03) (Table 5, Figure 2 ).
| D ISCUSS I ON
In the present study, TXA significantly reduced postoperative bleeding and allogeneic transfusion without a negative influence on morbidity or mortality in patients undergoing primary and isolated CABG. Furthermore, this study with a 7-year follow-up duration demonstrated the benefit of TXA on the incidence of myocardial infarction.
Massive hemorrhage and allogeneic transfusion are independent risk factors in patients undergoing CABG. 1 Antifibrinolytic treatment with TXA, aminocaproic acid, and aprotinin is effective in reducing bleeding and blood transfusion during cardiac surgery and has been recommended by established guidelines. 2 The strength of aprotinin is several times higher than that of TXA and aminocaproic acid and Intra-aortic balloon pumping (%)
Extracorporeal membrane oxygenation (%)
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The 7-year follow-up morbidity and mortality had been the most widely used agent prior to its discontinuation.
However, a series of studies suggested that aprotinin increases the incidence of mortality and renal insufficiency, and it was therefore suspended in 2008. 11 TXA has since become the primary antifibrinolytic drug.
Several meta-analyses and reviews have demonstrated the efficacy of TXA during cardiac surgery during the past 10 years.
4,5
The present study was a prospective, case-control superiority trial performed under the hypothesis that TXA can reduce postoperative bleeding and allogeneic blood transfusion in on-pump CABG surgery. We calculated the sample size according to the allogeneic RBC transfusion volume and ratio, and which were the primary end points of the study. We also followed the regimen of a loading dose of 10 mg/kg over 10 minutes and a maintenance rate of 10 mg/kg/h until the end of the operation, similar to the "recommendation 1" suggested by Dowd et al, 12 to achieve the lowest efficacious blood concentration of 334 µmol/L suggested by Horrow et al. 13 In the present study, TXA reduced the postoperative bleeding volume by 275 mL, allogeneic RBC volume by 2.05 units, and plasma transfused by 1.14 units. Furthermore, TXA decreased allogeneic RBC exposure by 19.6%, plasma exposure by 30.6%, and any allogeneic transfusion exposure by 14.4%.
TXA might have also reduced the incidence of major bleeding and reoperation for bleeding, although there were no significant differences between the two groups. These results are similar to This result is consistent with that of the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage 2 (CRASH-2) study, 15, 16 which showed that TXA significantly reduced the incidence of fatal and nonfatal myocardial infarction and did not affect venous thrombotic events, including pulmonary embolism and deep venous thrombosis, in patients with bleeding trauma. Therefore, the present study is the second to show that TXA may improve the prevalence of postoperative myocardial infarction after the CRASH-2 study.
This is an exciting and potentially important finding; however, we believe that the results should be interpreted with caution based on the rather small sample size and high rate of loss to follow-up. We F I G U R E 2 Occurrence of myocardial infarction consider that it may be related to the anti-inflammatory and antiplatelet activation effects of TXA, 17 which might play an important role in preventing myocardial infarction. The mechanisms in preventing long-term myocardial infarction involved in this finding require further study.
Tranexamic acid therapy for adult patients undergoing cardiac surgery is associated with a 4.1-fold increase in the risk of seizures.
18
A recent meta-analysis 6 showed that the risk of seizures increased in patients undergoing cardiac surgery or pulmonary endarterectomy with TXA exposure and that the incidence rate of TXA-associated seizures increased when the dose increased. The incidence rates of TXA-associated seizures at a low dose level, middle dose level, and high dose level were 1.4% (95% CI, 0.2%-2.5%), 2.4% (95% CI, 0.4%-4.4%), and 5.3% (95% CI: 3.3%-7.3%), respectively; therefore, low-dose TXA might not increase the incidence of seizures after cardiac surgery. In the current study, two (2.0%) patients in the TXA group and none in the placebo group developed seizures after the operation, which is consistent with the findings of the above-mentioned meta-analysis. Moreover, no seizures occurred in either group during the 7-years of follow-up after discharge. However, the relatively small sample size might have limited the ability to achieve statistical significance of our findings.
This study has several limitations. First, although a sample size of 210 patients provides convincing results regarding the effectiveness of TXA, which is the fundamental part of the hypothesis and the primary end point of the study, this sample size is a limitation with respect to analyzing the safety of TXA. We attempted to compensate for this limitation by performing a cautious long-term follow-up.
Second, although the follow-up duration was long enough to provide convincing evidence, the rate of loss to follow-up was 19.8%. The reason for this high rate of loss to follow-up was the limited economic condition of patients and poor communication mode. A higher rate of loss to follow-up may introduce bias to the long-term outcome.
However, we conducted a strict follow-up, and no cardiovascularrelated diseases were found except for myocardial infarction. Third, the present study excluded some high-risk patients, such as those with anemia, with renal and hepatic insufficiency, undergoing emergency procedures, and with a history of cardiac surgery. Therefore, was not a primary focus of this analysis.
To sum up, TXA significantly decreased postoperative bleeding and allogeneic transfusion in patients undergoing on-pump CABG.
The 7-year follow-up suggested that the use of TXA was safe and might play a potential role in the prevention of long-term myocardial infarction. Larger multicenter prospective controlled trials are needed to evaluate the effects of TXA on the long-term outcomes of cardiac surgery.
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